title: Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
abstract: Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.
authors: MHRP:HJF, Rockville, Maryland 20850, USA. mrolland@hivresearch.org
authors: Morgane
authors: M
authors: Rolland
authors: Peter
authors: P
authors: Gilbert
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D009626:Terminology as Topic
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX; D015483:HIV Antibodies